Collaborating to clobber COVID-19
NIH and FNIH are leading a public-private parternship to defeat COVID-19
An overlapping set of collaborations is focusing the combined intellectual, logistic and economic resources of the life sciences industry, government, academia and non-profits against SARS-Cov2, the virus that causes COVID-19.
The latest and broadest collaboration was disclosed Friday when NIH and the Foundation for the NIH (FNIH) announced Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership to coordinate and accelerate the development of medical countermeasures.
ACTIV membership includes 16 biopharma companies, FDA, CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA, the U.S. biodefense preparedness funding agency, which is backing at least eight COVID-19 programs, is part of ASPR.
Though EMA is involved in ACTIV, the partnership is focusing its activities on the U.S.
ACTIV has overlapping membership and is closely coordinating with two other consortia, one organized by the Gates Foundation and Novartis AG (NYSE:NVS; SIX:NOVN), and the other COVID R&D, a separate group of pharma R&D leaders that was first disclosed by BioCentury (see “Overlapping Collaborations”).